Arrowhead Pharmaceuticals Inc. (ARWR)
ARWR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$58.13
-4.28% on the day
Market cap
$8.2B
Mid cap
Revenue · 2025
$829.4M
+23258.2% on 2024
Net income · 2025
-$1.6M
-0.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ARWR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000879407 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $829.4M |
| Net income | -$1.6M |
| Operating income | $98.3M |
| Net margin | -0.2% |
| Operating margin | 11.9% |
| Revenue growth | +23258.2% |
| Cash | Not in SEC XBRL data |
| Total assets | $1.6B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-01-09 |
| Latest annual report | 10-K | 2025-11-25 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report | 8-K | 2026-08-04 |
| Latest proxy | DEFA14A | 2026-01-27 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.8% |
| 1 month | -18.0% |
| 3 months | -18.8% |
| Year to date | -12.7% |
| 1 year | +59.8% |
| From 52-week high | -35.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AXSM | Axsome Therapeutics Inc. | $156.32 | -5.83% | $8.2B |
| TGTX | TG Therapeutics Inc. | $54.34 | -1.68% | $8.3B |
| CYTK | Cytokinetics Incorporated | $61.62 | -1.86% | $8.6B |
| PTGX | Protagonist Therapeutics Inc. | $138.49 | -4.41% | $9.0B |
| ABVX | Abivax SA | $86.22 | -0.83% | $7.5B |
| SYRE | Spyre Therapeutics Inc. | $80.45 | -6.34% | $7.1B |
| IONS | Ionis Pharmaceuticals Inc. | $42.38 | -2.95% | $7.0B |
| AMRX | Amneal Pharmaceuticals Inc. | $19.57 | -2.30% | $6.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier